Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22436624 | 0.86 | NAAA (0.43) | NAAADNM1CA12CA1CA9 | |
| SCHEMBL28599459 | 0.73 | ALDH1A1 (0.40) | NAAADNM1CA12CA9 | |
| SCHEMBL29163447 | 0.72 | ALDH1A1 (0.46) | DNM1CA12CA1CA9MMP1 | |
| SCHEMBL10735427 | 0.72 | CA12 (0.39) | NAAADNM1CA12CA1CA9 | |
| SCHEMBL28214910 | 0.72 | CES1 (0.43) | DNM1CA12CA1CA9MMP1 | |
| SCHEMBL6312523 | 0.71 | DNM1 (0.50) | NAAADNM1 | |
| SCHEMBL28214917 | 0.71 | DNM1 (0.50) | NAAADNM1 | |
| SCHEMBL7799203 | 0.71 | DNM1 (0.46) | DNM1 | |
| SCHEMBL10890584 | 0.69 | CA12 (0.43) | DNM1CA12CA1CA9MMP1 | |
| SCHEMBL30964709 | 0.69 | DNM1 (0.44) | DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | NAAA 3420/4885DNM1 2053/4885CA12 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.